Close
Digital Health & Ai Innovation summit 2026
APE 2026

CELLINK launches a real-time qPCR instrument

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Natera Adds ctDNA-Based MRD Tests with...

In an all-stock transaction, Natera, which is the cell-free...

FDA Launches Technology-Enabled Meaningful Patient Outcomes

Technology-Enabled Meaningful Patient Outcomes – TEMPO has been launched...

US Healthcare Providers to Benefit from...

The federal government has formally withdrawn the Biden-era minimum...

CELLINK has started reselling a qPCR instrument. The instrument uses a laboratory technique of molecular biology based on the polymerase chain reaction. It monitors the amplification of a targeted DNA molecule during the PCR (i.e., in real time).

qPCR is a proven and stable technology with numerous applications. It is commonly used for both diagnostic and basic research. Uses of the technique in the industry include the quantification of microbial load in foods, the detection of GMOs (genetically modified organisms) and the quantification and genotyping of human viral pathogens such as SARS-CoV-2. The unit includes dual channels and is open source, allowing users to use any kit to run their samples. It is designed as a high-quality, low-throughput qPCR cycler. The instrument is easy to use and runs a sample in 20-40 minutes. CELLINK wants to help provide scientists with the tools they need to make a difference and therefore offers this instrument at a low-cost point to help advance research related to the COVID-19 pandemic.

Latest stories

Related stories

Natera Adds ctDNA-Based MRD Tests with Acquisition of Foresight Diagnostics

In an all-stock transaction, Natera, which is the cell-free...

FDA Launches Technology-Enabled Meaningful Patient Outcomes

Technology-Enabled Meaningful Patient Outcomes – TEMPO has been launched...

US Healthcare Providers to Benefit from Minimum Nurse Staffing Rule Repeal

The federal government has formally withdrawn the Biden-era minimum...

Purehealth, Dorchester Partner to Bring Luxury Hospitality in Healthcare

PureHealth has gone on to announce a first-of-its-kind partnership...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »